These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29494756)

  • 1. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
    Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
    Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
    Melin A; Routier E; Tissot H; Rouleau E; Robert C
    Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
    [No Abstract]   [Full Text] [Related]  

  • 8. Response of BRAF
    Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF L597K mutation: an opportunity to treat.
    Lobo-Martins S; Pais HL; Soares-de-Almeida L; Costa L; Mansinho A; Teixeira de Sousa R
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
    Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
    J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
    [No Abstract]   [Full Text] [Related]  

  • 12. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Therapy Improves Colorectal Cancer Response.
    Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting
    Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
    Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
    Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.